Mersana Therapeutics, Inc. Common Stock
MRSNMersana Therapeutics, Inc. is a biotechnology company focused on developing innovative antibody drug conjugates (ADCs) for the treatment of cancer. Founded in 2014, the company leverages its proprietary platform to design and develop highly targeted therapies aimed at difficult-to-treat tumors, with an emphasis on delivering potent medicines directly to cancer cells while minimizing damage to healthy tissue.
Company News
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in recent merger and acquisition transactions.
Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for up to $285 million, expanding its oncology pipeline with a focus on developing antibody-drug conjugates targeting cancers, particularly in pediatric and triple-negative breast cancer treatments.
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 11.11% and 5.18%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Mersana Therapeutics suffered a major trial failure for its lead candidate in July, causing a significant drop in stock value. Read more on MRSN stock here.
Mersana's stock tumbles 58% to mark its biggest-ever one-day percentage decline since going public in 2018.
